Placulumab

Monoclonal antibody

Pharmaceutical compound

Placulumab
Monoclonal antibody
Type	?
Source	Human
Target	TNF
Clinical data
ATC code	none
Identifiers
CAS Number	945781-29-3
ChemSpider	none
UNII	S80W9W569L
KEGG	D10320
Chemical and physical data
Formula	C₃₄₀₄H₅₂₆₂N₉₀₂O₁₀₃₆S₂₂
Molar mass	76104.14 g·mol⁻¹

Placulumab is a human monoclonal antibody designed for the treatment of inflammatory diseases.^[1]

This drug was developed by Teva Pharmaceutical Industries, Inc. As of 2012, development of placulumab has been discontinued.^[2]

References

[edit ]

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Placulumab, American Medical Association .
^ Antoniu SA (November 2013). "Discontinued drugs for pulmonary, allergy, gastrointestinal, arthritis (2012)". Expert Opinion on Investigational Drugs. 22 (11): 1453–64. doi:10.1517/13543784.2013.836489. PMID 24024675.

v
t
e

Monoclonal antibodies for the immune system

Immune system

Human	Immunosuppression : Abrilumab Adalimumab ^# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Garadacimab Golimumab Ianalumab ^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Nipocalimab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab ^† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab ^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive: Apolizumab ^§ Aselizumab Atezolizumab Benralizumab Camrelizumab ^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab ^‡ Epratuzumab Erlizumab Etrolizumab ^† Fontolizumab Frexalimab ^† Inebilizumab Itolizumab Lampalizumab ^† Letolizumab Ligelizumab ^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab (+berahyaluronidase alfa) Pexelizumab Pidilizumab Plozalizumab PRO 140 ^† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab ^† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412 ^§ Immune activation: Dostarlimab Other: Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab ^† Lebrikizumab Olokizumab ^† Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatory lesions

Mouse	Besilesomab Fanolesomab ^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=Placulumab&oldid=1277211701"